Drugmaker AbbVie Inc said on Tuesday it would buy Botox-maker Allergan Plc for about $63 billion, grabbing control of by far the biggest name in medical aesthetics to help reduce its reliance on blockbuster arthritis treatment Humira.
Latest posts by Reuters News (see all)
- Strong data, earnings drive Wall Street to new highs - January 17, 2020
- Mexico hails USMCA trade deal approval, expects more investment - January 17, 2020
- Trump taps lawyer Dershowitz, others for impeachment trial defense - January 17, 2020